Intensity reports have become more likely at Investing.com’s Sarkom-Behandlung

SHELTON, Conn. – Intensity Therapeutics, Inc. (NASDAQ: INTS), one of the immunobasic Krebstherapies, specialized in biotechnology, presented kürzlich dating from clinical Phase-1/2-Study with INT230-6, a new intratumoral injection with treatment with verschiedener Sarkome. The study medicine, which has an improved median gesamtüberlebensrate (mOS) and a powerful Sicherheitsprofil examination, appeared at the annual trial of the Connective Tissue Oncology Society on 16.11.2024.

In the study, 15 refractory patients were treated with the INT230-6 as monotherapy. The ergebnisse has viewed a mOS of 21.3 monates, a significant scaffolding in the representation of the 6.7 monates, which works in a synthetic control group. If we look at the high-quality treatment, T-Zellen inner half of the tumor would be activated and had a good health profile, since 20% of the probands have undergone treatment without any serious injuries, all of which were grade 3.

The INVINCIBLE-3 trial, a global randomized phase 3 trial completed over time, is a study and investigation of INT230-6 in standard chemotherapy in patients with improved evaluation. This study investigated the souls of the 333 patients with disease, liposome and undifferentiated Sarkom ab in the US, Canada, Europe and Australia.

INT230-6, with the proprietary DfuseRx™ technology platform of the Intensity technology, bestht with cisplatin, vinblastinulfat and a penetration enhancer, the action of the inner medicine of tumors is effective. The therapy is heart-warming, the immunological treatment will lead to immunosuppression, treatment with systemic chemotherapy is possible.

Intensity’s President and CEO, Lewis H. Bender, who demonstrated the potential of INT230-6, has helped patients with metastases prolong and increase their quality of life, offsetting the poisoning in the future. This hospital’s research results in drug treatment lasting longer than 200 patients in clinical trials.

The information for those messages is based on a press conference.

In others, the following activities have been carried out by Intensity Therapeutics as Chief Financial Officer, Joseph Talamo, and the Principal Accounting Officer, John Wesolowski, Aktienoptionen gewährt. It is the part of the 2021 Stock Incentive Plan of the Unternehmens, which means that the interest will increase with the denen of the Unternehmens and der Aktionäre in Einklang to kill. The third generation has launched the Employee Stock Purchase Plan (ESPP) for 2024 and initiated an At-The-Market (ATM) investment with an amount of US$15 million, from the investment bank HC Wainwright & Co. has passed through time.

Darüber has shown the Intensity Therapeutics of Brookline Capital Markets a Kaufempfehlung, the potential intratumoral Wirkstoffabgabetechnologie revorheb. The third part of the world has conducted a phase 3 trial for its INT230-6 monotherapy and has a phase 2/3 trial focusing on breast cancer.

Among others, Entwicklungen hát Intensity Therapeutics zwei Class I Directors gewählt and EisnerAmper LLP as unaffiliated registrierte Wirtschaftsprüfungsgesellschaft until 31.12.2024 endende Geschäftsjahr bestätigt. This study was conducted on the date of pathological completion of a phase 2 partner study in Europe in mid-2025.

InvestingPro Insights

Während Intensity Therapeutics (NASDAQ: INTS) has been heavily researching clinical trials for the INT230-6 power, exploring some financial knowledge and experience with InvestingPro. The market capitalization of the Unternehmens had a value of US$43.38 million and was an active position as Small-Cap Biotechnology Unternehmen more broadly mirrored.

InvestPro-Daten look, the Intensity Therapeutics in the last month of the month are not a profitable war, with a clean surgical experience of -16.73 Million US-Dollars. It goes into the Einklang with the Fokus des Unternehmens op Forschung und Entwicklung in the blessing Vorrevenuen-Phase. The negative mirror is wider in the Basic EPS (Fortgeführte Geschäfte) of -1.18 US Dollars.

Most clinical trials have a high probability that the INTS action will be volatile. The trend of business activities started at -63.24% years ago, but it was pushed a bit into the underlying activity. The fact is that the 1-year trend of business activity was 50% likely to lag behind a longer positive trend, the optimism of pipeline growth from the broader mirror of the pipeline.

InvestingPro-Tipps I said, the moderately leveraged Intensity Therapeutics had assured funding flexibility on the most clinical programs possible. The Unternehmen led to a large profit margin, which was not unchanged for the Biotechnology Unternehmen in the Frühphase, which invested heavily in F&E.

For the first time, seeing the INTS in Betracht, it is important to be on the beach, that the Action was traded with a high Kurs-Buchwert-Verhaal of 15.61, was on the Market War for the zukünftiges Wachstum based on the Potenzial von INT230-6 and others Pipeline -Candidates hindeuten könnte.

Anleger, die eener tieferen Analyze interests, find 5 zeetzliche In

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.